Tatva Chintan Pharma Chem Share Price

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, revenue stood at Rs 1,341.44 million, representing a YoY increase of 24.36% from Rs 1,078.64 million in Q4FY25 and a QoQ increase of 2.14% from Rs 1,313.34 million in Q3FY26. Total Income: The total income for Q4FY26 was Rs 1,337.96 million, compared to Rs 1,085.86 million in Q4FY25 (up 23.22% YoY) and Rs 1,330.68 million in Q3FY26 (up 0.55% QoQ). Net Profit: The company reported a net profit of Rs 103.21 million in Q4FY26, marking a significant YoY increase of 902.04% from Rs 10.30 million in Q4FY25, but a QoQ decrease of 31.94% from Rs 151.65 million in Q3FY26. Annual Performance (FY26): Revenue from operations for the full year FY26 was Rs 5,058.58 million, up 32.18% from Rs 3,827.14 million in FY25. Net profit for FY26 increased by 636.11% to Rs 420.54 million from Rs 57.13 million in FY25. Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 stood at Rs 4.41, compared to Rs 0.44 in Q4FY25 and Rs 6.49 in Q3FY26. For the full year FY26, EPS was Rs 17.98. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q4FY26 was Rs 1,326.65 million, up 23.24% YoY from Rs 1,076.48 million in Q4FY25 and down 4.27% QoQ from Rs 1,385.88 million in Q3FY26. Total Income: Total standalone income for Q4FY26 was Rs 1,322.96 million, compared to Rs 1,089.43 million in Q4FY25 and Rs 1,403.22 million in Q3FY26. Net Profit: Standalone net profit for Q4FY26 was Rs 90.23 million, up 724.02% YoY from Rs 10.95 million in Q4FY25 and down 43.55% QoQ from Rs 159.84 million in Q3FY26. Annual Performance (FY26): Standalone revenue from operations for the full year FY26 reached Rs 4,962.96 million, an increase of 35.45% from Rs 3,664.15 million in FY25. Net profit for FY26 stood at Rs 390.82 million, a massive increase compared to Rs 3.27 million in FY25. Business Highlights: Segment Performance: The company operates in only one reportable business segment, which is Specialty Chemicals. Dividend: The Board of Directors recommended a final dividend of Rs 2/- (20%) per equity share of face value Rs 10/- each for the financial year 2025-26, subject to shareholder approval. Auditor Appointments: The Board approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor of the company for the financial year 2026-27. Subsidiaries: The consolidated financial results include the results of two subsidiaries: Tatva Chintan USA Inc. and Tatva Chintan Europe B.V. Result PDF

• Trendlyne
• 2 weeks ago

Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 4 months 1 week ago

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q3FY26 results Revenue: Rs 1,313.34 crore against Rs 858.96 crore during Q3FY25. PBT: Rs 176.58 crore against Rs -2.35 crore during Q3FY25. PAT: Rs 151.65 crore against Rs 1.38 crore during Q3FY25. EPS: Rs 6.49 for Q3FY26. Result PDF

• Trendlyne
• 4 months 1 week ago